Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

An Easy Landing? Cephalon Scores Priority Review For Nuvigil In Jet Lag Disorder

This article was originally published in The Pink Sheet Daily

Executive Summary

Some, however, remain skeptical of the medicine's potential after the Provigil patent expires.
Advertisement

Related Content

FDA Pushes Back Action Date For Nuvigil Label Expansion Due To New Data
FDA Pushes Back Action Date For Nuvigil Label Expansion Due To New Data
Priority Review's Luster Dims In "Safety First Era" But Retains Value - Parexel
Nuvigil Jet Lag Indication Could Triple Potential Patients
FDA Approves Cephalon’s Nuvigil With Bolded Warning For Rash
FDA Approves Cephalon’s Nuvigil With Bolded Warning For Rash

Topics

Advertisement
UsernamePublicRestriction

Register

PS070020

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel